Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON2: Platform Trial For Relapsed Neuroblastoma
NCT07334301Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of bevacizumab, Dinutuximab beta in neuroblastoma, sponsored by University of Birmingham. Started Nov 2024; status: recruiting.
02
Drugs
bevacizumabDinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07334301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334301.